JP7502197B2 - セピアプテリン血漿曝露を増加させるための方法 - Google Patents

セピアプテリン血漿曝露を増加させるための方法 Download PDF

Info

Publication number
JP7502197B2
JP7502197B2 JP2020566655A JP2020566655A JP7502197B2 JP 7502197 B2 JP7502197 B2 JP 7502197B2 JP 2020566655 A JP2020566655 A JP 2020566655A JP 2020566655 A JP2020566655 A JP 2020566655A JP 7502197 B2 JP7502197 B2 JP 7502197B2
Authority
JP
Japan
Prior art keywords
sepiapterin
administration
food
pharma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020566655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525729A (ja
JPWO2019232130A5 (enExample
Inventor
ニール スミス，
ジョナサン レイス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics MP Inc
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of JP2021525729A publication Critical patent/JP2021525729A/ja
Publication of JPWO2019232130A5 publication Critical patent/JPWO2019232130A5/ja
Priority to JP2024015822A priority Critical patent/JP2024069192A/ja
Application granted granted Critical
Publication of JP7502197B2 publication Critical patent/JP7502197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2020566655A 2018-05-30 2019-05-30 セピアプテリン血漿曝露を増加させるための方法 Active JP7502197B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024015822A JP2024069192A (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US62/677,943 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US62/771,398 2018-11-26
US201962822376P 2019-03-22 2019-03-22
US62/822,376 2019-03-22
GC2019-37663 2019-05-28
GC201937663 2019-05-28
PCT/US2019/034523 WO2019232130A1 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024015822A Division JP2024069192A (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Publications (3)

Publication Number Publication Date
JP2021525729A JP2021525729A (ja) 2021-09-27
JPWO2019232130A5 JPWO2019232130A5 (enExample) 2022-06-03
JP7502197B2 true JP7502197B2 (ja) 2024-06-18

Family

ID=68699037

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566655A Active JP7502197B2 (ja) 2018-05-30 2019-05-30 セピアプテリン血漿曝露を増加させるための方法
JP2024015822A Pending JP2024069192A (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024015822A Pending JP2024069192A (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Country Status (20)

Country Link
US (2) US11617752B2 (enExample)
EP (2) EP3801536B1 (enExample)
JP (2) JP7502197B2 (enExample)
CN (1) CN112703002A (enExample)
AU (2) AU2019277382B2 (enExample)
CA (1) CA3102106A1 (enExample)
DK (1) DK3801536T3 (enExample)
ES (1) ES2986920T3 (enExample)
FI (1) FI3801536T3 (enExample)
HR (1) HRP20241213T1 (enExample)
HU (1) HUE068589T2 (enExample)
LT (1) LT3801536T (enExample)
MD (1) MD3801536T2 (enExample)
MX (2) MX2020012979A (enExample)
PL (1) PL3801536T3 (enExample)
PT (1) PT3801536T (enExample)
RS (1) RS65874B1 (enExample)
SI (1) SI3801536T1 (enExample)
SM (1) SMT202400430T1 (enExample)
WO (1) WO2019232130A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
KR102561697B1 (ko) 2016-11-29 2023-07-28 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 다형체 및 그의 염
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
US20230077104A1 (en) * 2020-02-19 2023-03-09 The United States Government As Represented By The Department Of Veteran Affairs L-sepiapterin and methods of use for treating diseases and disorders
US20240122931A1 (en) * 2021-02-09 2024-04-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) * 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
CN120732846A (zh) * 2025-04-09 2025-10-03 中南大学湘雅医院 吲哚乙酸在制备预防或治疗高血压产品中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523708A (ja) 2007-04-11 2010-07-15 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US20130108694A1 (en) 2011-11-02 2013-05-02 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
JP2002515965A (ja) 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
CA2543315A1 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
CN1894251B (zh) 2003-11-17 2011-06-29 默克和西伊公司 (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
MX2007005039A (es) 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.
EP1819340A2 (en) 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US7582799B2 (en) 2005-04-28 2009-09-01 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
TR201910287T4 (tr) 2008-08-12 2019-07-22 Orpha Swiss Gmbh Tetrahidrobiopterin ihtiva eden farmasötik dozaj şekli.
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
RU2661033C9 (ru) 2011-03-01 2018-10-23 Дифарма С.А. Стабильные композиции тетрагидробиоптерина
EP2848619B1 (en) 2012-05-07 2018-07-11 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin
US10365267B2 (en) * 2014-10-31 2019-07-30 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
KR102561697B1 (ko) 2016-11-29 2023-07-28 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 다형체 및 그의 염
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
CN111328414B (zh) * 2017-11-23 2022-09-23 株式会社半导体能源研究所 显示装置及电子设备
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
EP3807279B1 (en) 2018-05-30 2025-12-31 PTC Therapeutics MP, Inc. Pharmaceutically acceptable sepiapterin salts with improved stability
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
CN114650825A (zh) 2019-09-25 2022-06-21 Ptc医疗Mp公司 治疗高苯丙氨酸血症的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523708A (ja) 2007-04-11 2010-07-15 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
WO2011132435A1 (ja) 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US20130108694A1 (en) 2011-11-02 2013-05-02 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinica Chimica Acta，1979年，Vol.93，p.251-262

Also Published As

Publication number Publication date
JP2021525729A (ja) 2021-09-27
PT3801536T (pt) 2024-09-19
US20210220363A1 (en) 2021-07-22
HUE068589T2 (hu) 2025-01-28
EP3801536A1 (en) 2021-04-14
SMT202400430T1 (it) 2024-11-15
EP4454704A3 (en) 2025-01-01
EP4454704A2 (en) 2024-10-30
MD3801536T2 (ro) 2024-11-30
PL3801536T3 (pl) 2025-02-03
DK3801536T3 (da) 2024-08-19
WO2019232130A1 (en) 2019-12-05
AU2025200814A1 (en) 2025-02-27
MX2024005935A (es) 2024-06-04
US20230381181A1 (en) 2023-11-30
FI3801536T3 (fi) 2024-08-29
US12329757B2 (en) 2025-06-17
SI3801536T1 (sl) 2024-12-31
RS65874B1 (sr) 2024-09-30
EP3801536A4 (en) 2022-03-23
US11617752B2 (en) 2023-04-04
AU2019277382A1 (en) 2021-01-21
ES2986920T3 (es) 2024-11-13
JP2024069192A (ja) 2024-05-21
CN112703002A (zh) 2021-04-23
HRP20241213T1 (hr) 2024-11-22
LT3801536T (lt) 2024-09-25
AU2019277382B2 (en) 2025-01-09
MX2020012979A (es) 2021-04-29
CA3102106A1 (en) 2019-12-05
EP3801536B1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
JP7502197B2 (ja) セピアプテリン血漿曝露を増加させるための方法
JP7547215B2 (ja) テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
US12213982B2 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
JP7778477B2 (ja) セピアプテリンの薬学的に許容される塩
HK40119071A (en) Methods for increasing sepiapterin plasma exposure
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
US20240115572A1 (en) Methods for treating glioblastomas with sepiapterin
BR112020024346A2 (pt) métodos para aumentar a exposição de sepiapterina no plasma
HK40087700A (zh) 墨蝶呤的药学上可接受的盐

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240606

R150 Certificate of patent or registration of utility model

Ref document number: 7502197

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150